INTERIM REPORT JANUARY-MARCH 2010

INTERIM REPORT JANUARY-MARCH 2010 

KARO BIO'S PROJECTS ARE PROGRESSING

•	Net sales for the period amounted to MSEK - (2.2) 
•	Net loss for the period amounted to MSEK 40.5 (45.9) 
•	Loss per share amounted to SEK 0.26 (0.36)
•	Cash flow from operating activities for the period amounted to MSEK -43.0
(-41.0). Cash, cash equivalents and other short-term investments totaled MSEK
192.7 (200.4) at the end of the period 
•	On March 11, The New England Journal of Medicine published clinical phase II
results on eprotirome and its ability to further reduce serum LDL cholesterol
levels in statin-treated patients
•	Fredrik Lindgren was appointed new President and CEO of Karo Bio and will on
April 23 succeed Per Olof Wallström, who has resigned after five years with the
company 

For further information, please contact:
Per Olof Wallström, President, tel. +46 8 608 60 20
Erika Söderberg Johnson, Chief Financial Officer, tel. +46 8 608 60 52

Legal disclaimer
This financial report includes statements that are forward looking and actual
results may differ materially from those stated. In addition to the factors
discussed, among other factors that may affect results are development within
research programs, including development in preclinical and clinical trials, the
impact of competing research programs, the effect of economic conditions, the
effectiveness of the Company's intellectual property rights and preclusions of
potential third party's intellectual property rights, technological development,
exchange rate and interest rate fluctuations, regulatory and political risks.

The information is of a nature that Karo Bio shall need to disclose according to
the Securities 
Market Act. The information was disclosed on April 22, 2010, 08:30 am